(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Edgewise Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast EWTX's revenue for 2026 to be $1,961,374,107, with the lowest EWTX revenue forecast at $1,961,374,107, and the highest EWTX revenue forecast at $1,961,374,107. On average, 3 Wall Street analysts forecast EWTX's revenue for 2027 to be $7,470,313,581, with the lowest EWTX revenue forecast at $4,116,083,662, and the highest EWTX revenue forecast at $9,889,061,450.
In 2028, EWTX is forecast to generate $20,644,863,458 in revenue, with the lowest revenue forecast at $8,590,818,589 and the highest revenue forecast at $31,114,865,238.